Foresee Pharmaceuticals announced on the 9th that its consolidated revenue for June was approximately NT$38.86 million, representing a 179% increase from May and a 22% rise year-on-year. The cumulative consolidated revenue for the first half of this year reached about NT$222 million, marking a 12% year-on-year growth.

June’s consolidated revenue includes sales revenue of NT$27.45 million from CAMCEVI’s six-month formulation in the U.S. terminal market, sales royalties of NT$11.31 million, and service income of NT$100,000 recognized according to the progress of outsourced consulting for the U.S. NDA filing of CAMCEVI’s three-month formulation.

Foresee stated that the sales volume of CAMCEVI’s six-month formulation in the U.S. terminal market reached 2,297 units in June, up about 15% from 1,991 units in May. This sales volume set a new monthly high for this year and is the second-highest monthly record since its U.S. launch in April 2022.

The regulatory applications for CAMCEVI’s three-month formulation in both Europe and the U.S. have smoothly entered substantive review, with the U.S. PDUFA target date set for August 29. Related revenues for CAMCEVI this year are expected to see a significant increase compared to the previous year, supported by milestone payments upon approval of the three-month formulation in the U.S.

Resource: 逸達6月營收3,886萬元、月增179% 上半年2.2億元、年增12%